首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Anti-obesity and anti-diabetic effects of a standardized potato extract in ob/ob mice
【2h】

Anti-obesity and anti-diabetic effects of a standardized potato extract in ob/ob mice

机译:标准的马铃薯提取物对ob / ob小鼠的抗肥胖和抗糖尿病作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The potato (Solanum tuberosum) has been cultivated globally for food for millenia. Potato contains proteinase inhibitor II, which catalyzes the release of cholecystokinin (CCK), leading to delayed gastric emptying in humans. The present study investigated the anti-obesity effects of Slendesta™ Potato Extract (SLD), a standardized potato extract containing 5% proteinase inhibitor II, in the ob/ob obese mice. Three doses of SLD (50, 150 or 300 mg/kg) were orally administered to ob/ob mice once a day for 28 days, whereas control mice were administered distilled water. Four weeks after SLD treatment, the changes in body weight, food consumption, epididymal fat weight, serum chemistry, insulin, leptin and adiponectin contents, and fat histopathology were determined and compared with ob/ob mice treated with 750 mg/kg conjugate linoleic acid. As a result of SLD treatment in the obese mice, body weight, food consumption, epididymal fat, serum biochemistry, histomorphological changes of fat and pancreas were significantly and dose-dependently decreased compared with ob/ob control mice. These obesity and type 2 diabetes associated alterations were significantly inhibited after SLD treatment for 28 days. Thus, the present results indicate that SLD has potential as an alternative therapeutic agent for obesity.
机译:马铃薯(Solanum tuberosum)已在全球种植,可作为千年食物。马铃薯中含有蛋白酶抑制剂II,该酶催化胆囊收缩素(CCK)的释放,导致人类胃排空延迟。本研究调查了Slendesta™马铃薯提取物(SLD)(一种含有5%蛋白酶抑制剂II的标准化马铃薯提取物)对肥胖小鼠的抗肥胖作用。每天一次对ob / ob小鼠口服三剂SLD(50、150或300 mg / kg),持续28天,而对小鼠则给予蒸馏水。 SLD治疗后四周,测定体重,食物消耗,附睾脂肪重量,血清化学,胰岛素,瘦素和脂联素含量以及脂肪组织病理学的变化,并与用750 mg / kg共轭亚油酸治疗的ob / ob小鼠进行比较。作为肥胖小鼠SLD治疗的结果,与ob / ob对照小鼠相比,体重,食物消耗,附睾脂肪,血清生物化学,脂肪和胰腺的组织形态学变化显着且剂量依赖性降低。 SLD治疗28天后,这些与肥胖和2型糖尿病相关的改变得到了显着抑制。因此,本结果表明SLD具有作为肥胖症的替代治疗剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号